Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea - Full Text View

Sponsor:	Nycomed US Inc.
Information provided by:	Nycomed US Inc.
ClinicalTrials.gov Identifier:	NCT01016782

Purpose

The aim of this trial is to assess the efficacy of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea.

Treatment medication will be administered as follows: A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days.

Condition	Intervention	Phase
Inflammatory Rosacea	Drug: 0444	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment
Official Title:	Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0444 Gel

Resource links provided by NLM:

MedlinePlus related topics: Rosacea

U.S. FDA Resources

Further study details as provided by Nycomed US Inc.:

Primary Outcome Measures:

Reduction in the number of papules and pustules from Baseline to End of Treatment [ Time Frame: 70 Days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Reduction in the Investigator's Global Evaluation, Clear or Almost Clear [ Time Frame: 70 Days ] [ Designated as safety issue: No ]

Enrollment:	867
Study Start Date:	January 2008
Study Completion Date:	July 2009
Primary Completion Date:	July 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Test: Experimental Test product that contains active pharmaceutical ingredient	Drug: 0444 A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
Reference: Active Comparator Reference product that contains active pharmaceutical ingredient	Drug: 0444 A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
Vehicle: Placebo Comparator Placebo that contains no active pharmaceutical ingredient	Drug: 0444 A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Clinical diagnosis of rosacea
Good health with the exception of rosacea
Papsules and pustules minimum and maximum requirements

Exclusion Criteria:

Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period.
Subjects who have any systemic or dermatological disorders with the exception of rosacea

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01016782

Sponsors and Collaborators

Nycomed US Inc.

Investigators

Study Director:

Kathleen Ocasio, CCRA

Nycomed US Inc.

More Information

No publications provided

Responsible Party:	Nycomed US Inc. ( Kathleen Ocasio, CCRA )
Study ID Numbers:	0444
Study First Received:	November 17, 2009
Last Updated:	November 18, 2009
ClinicalTrials.gov Identifier:	NCT01016782 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Nycomed US Inc.:

Inflammatory Rosacea
Rosacea

Additional relevant MeSH terms:

Rosacea
Skin Diseases

ClinicalTrials.gov processed this record on February 08, 2010